Torres, Tiago http://orcid.org/0000-0003-0404-0870
Sohrt Petersen, Anne http://orcid.org/0000-0001-7286-5239
Ivens, Ulla http://orcid.org/0009-0008-2381-7327
Bosch Vilaro, Albert http://orcid.org/0009-0004-2806-808X
Stinson, John http://orcid.org/0009-0009-5230-574X
Carrascosa, José Manuel http://orcid.org/0000-0003-4266-0771
Funding for this research was provided by:
LEO Pharma
Article History
Received: 9 February 2024
Accepted: 15 March 2024
First Online: 13 April 2024
Declarations
:
: Tiago Torres has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, and UCB. Anne Sohrt Petersen, Ulla Ivens, Albert Bosch Vilaro, and John Stinson are employees of LEO Pharma. José Manuel Carrascosa has participated as PI/SI and/or invited speaker and/or adviser for LEO Pharma, Sanofi, Pfizer, Almirall, Lilly, AbbVie, AMGEN, and Galderma.
: This analysis is based on previously conducted studies and does not contain data from any new studies with human participants or animals.